HC Wainwright Reiterates “Buy” Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $12.00 price objective on the stock.

Separately, Jones Trading dropped their target price on Femasys from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th.

Femasys Stock Up 0.3%

Shares of FEMY opened at $0.98 on Wednesday. The company has a quick ratio of 0.54, a current ratio of 0.93 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $1.02 and a 200 day moving average of $1.19. The company has a market cap of $25.12 million, a PE ratio of -1.08 and a beta of -2.62. Femasys has a 52-week low of $0.69 and a 52-week high of $1.80.

Femasys (NASDAQ:FEMY) last announced its earnings results on Thursday, May 8th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.06). Femasys had a negative net margin of 1,242.06% and a negative return on equity of 392.45%. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.14 million. On average, sell-side analysts expect that Femasys will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FEMY. Dauntless Investment Group LLC purchased a new position in Femasys in the first quarter worth $1,969,000. Clear Creek Financial Management LLC raised its stake in Femasys by 5.5% in the first quarter. Clear Creek Financial Management LLC now owns 270,371 shares of the company’s stock valued at $338,000 after buying an additional 14,000 shares during the last quarter. Geode Capital Management LLC raised its stake in Femasys by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock valued at $238,000 after buying an additional 9,681 shares during the last quarter. Northern Trust Corp boosted its holdings in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after acquiring an additional 37,675 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Femasys during the 4th quarter valued at approximately $45,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.